METHODS OF TREATING JUVENILE TYPE 1 DIABETES MELLITUS

• US 20080227846A1
• Filed: 03/13/2008
• Published: 09/18/2008
• Est. Priority Date: 03/13/2007
• Status: Abandoned Application

• Current Assignee: MUSC Foundation For Research Development (State of South Carolina)
• Original Assignee: Medical University of South Carolina (State of South Carolina), MUSC Foundation For Research Development (State of South Carolina)
• Inventors: Singh, Inderjit, Key, Lyndon
• Application Number:
  US12/047,871
• Publication Number:
  US 20080227846A1
• Time in Patent Office: Days
• US Class Current: 514/419
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/22 of acyclic acids, e.g. pravastatin
• CPC Class Codes: A61K 31/366 having six-membered rings, e.g. delta-lactones
• CPC Class Codes: A61K 31/40 having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• CPC Class Codes: A61K 31/405 Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
• CPC Class Codes: A61K 31/44 Non condensed pyridines; Hydrogenated derivatives thereof
• CPC Class Codes: A61K 31/47 Quinolines; Isoquinolines
• CPC Class Codes: A61K 31/505 Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics

Abstract

The present disclosure describes methods for treating or preventing Type 1 diabetes mellitus in juveniles, particularly in juveniles newly diagnosed with Type 1 diabetes. This prevention or treatment of Type 1 diabetes is achieved by administering one or more therapeutic agents to a juvenile in need, wherein the therapeutic agent is, for example, a competitive inhibitor of mevalonate synthesis, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, or an inducer of AMP protein kinase (AMPK) activity. In certain embodiments, juveniles with Type 1 diabetes are treated with an HMG-CoA reductase inhibitor such as a statin, thereby decreasing the destruction of islet cells, or maintaining endogenous insulin production, in the juvenile.

Claims

1. A method of treating type 1 diabetes mellitus in a juvenile patient in need of treatment comprising:

(a) identifying a juvenile patient diagnosed with type 1 diabetes mellitus with functioning islet cells, and

(b) administering one or more therapeutic agents to the patient in an amount sufficient to maintain or increase the function of the islet cells in the patient,

wherein the therapeutic agents are selected from the group consisting of an inhibitor of mevalonate synthesis, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, an inducer of AMP protein kinase (AMPK) activity, an inhibitor of dual peroxisome proliferators activated receptor (PPAR) activity, an inhibitor of mevalonic-acid pyrophosphate decarboxylase, an inhibitor of the conversion of isopententyl pyrophosphate (IPP) to farnesyl pyrophosphate (FPP), an inhibitor of the isoprenylation of proteins, an inhibitor of the induction of NF-kβ

, an inhibitor of the farnesylation of Ras, an inhibitor of cAMP phosphodiesterase, an antioxidant that blocks LPS- and cytokine-induced production of NO, an enhancer of intracellular levels of cAMP, and any combinations thereof.

2. The method of claim 1, wherein the therapeutic agent is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.

3. The method of claim 2, wherein the inhibitor of HMG-CoA reductase is a statin or a pharmaceutically-acceptable salt, derivative, analog, prodrug, or solvate thereof.

4. The method of claim 3, wherein the statin is selected from the group consisting of lovastatin, mevastatin, atorvastatin, fluvastatin, cerivastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin.

5. The method of claim 1, wherein the function of the islet cells in the patient is maintained.

6. The method of claim 1, wherein the function of the islet cells in the patient increases.

7. A method of treating type 1 diabetes mellitus in a juvenile patient in need of treatment comprising:

(a) identifying a juvenile patient diagnosed with type 1 diabetes mellitus with endogenous insulin secretion, and

(b) administering one or more therapeutic agents to the patient in an amount sufficient to maintain or increase the endogenous insulin secretion in the patient,

wherein the therapeutic agents are selected from the group consisting of an inhibitor of mevalonate synthesis, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, an inducer of AMP protein kinase (AMPK) activity, an inhibitor of dual peroxisome proliferators activated receptor (PPAR) activity, an inhibitor of mevalonic-acid pyrophosphate decarboxylase, an inhibitor of the conversion of isopententyl pyrophosphate (IPP) to farnesyl pyrophosphate (FPP), an inhibitor of the isoprenylation of proteins, an inhibitor of the induction of NF-kβ

, an inhibitor of the farnesylation of Ras, an inhibitor of cAMP phosphodiesterase, an antioxidant that blocks LPS- and cytokine-induced production of NO, an enhancer of intracellular levels of cAMP, and any combinations thereof.

8. The method of claim 7, wherein the endogenous insulin secretion in the patient is maintained.

9. The method of claim 7, wherein the endogenous insulin secretion in the patient increases.

10. A method of prolonging the honeymoon period of type 1 diabetes mellitus in a juvenile patient in need thereof comprising:

(a) identifying a juvenile patient in the honeymoon period of type 1 diabetes mellitus, and

(b) administering one or more therapeutic agents to the patient, wherein the one or more therapeutic agents are selected from the group consisting of an inhibitor of mevalonate synthesis, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, an inducer of AMP protein kinase (AMPK) activity, an inhibitor of dual peroxisome proliferators activated receptor (PPAR) activity, an inhibitor of mevalonic-acid pyrophosphate decarboxylase, an inhibitor of the conversion of isopententyl pyrophosphate (IPP) to farnesyl pyrophosphate (FPP), an inhibitor of the isoprenylation of proteins, an inhibitor of the induction of NF-kβ

, an inhibitor of the farnesylation of Ras, an inhibitor of cAMP phosphodiesterase, an antioxidant that blocks LPS- and cytokine-induced production of NO, an enhancer of intracellular levels of cAMP, and any combinations thereof,

wherein the administration of the one or more therapeutic agents results in a prolonged honeymoon period in the juvenile patient.

11. The method of claim 10, wherein the juvenile patient in the honeymoon period requires less than 0.5 U/kg/day of insulin.

12. The method of claim 10, wherein the juvenile patient in the honeymoon period has a hemoglobin A1c level equal to or less than 6%.

13. The method of claim 12, wherein the juvenile patient requires less than 0.5 U/kg/day of insulin.

14. A method of preventing type 1 diabetes mellitus in a juvenile at risk of developing type 1 diabetes mellitus comprising:

(a) identifying a juvenile patient at risk for developing type 1 diabetes mellitus, and

(b) administering one or more therapeutic agents to the patient in an amount sufficient to prevent the onset of type 1 diabetes mellitus in the patient,

wherein the therapeutic agents are selected from the group consisting of an inhibitor of mevalonate synthesis, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, an inducer of AMP protein kinase (AMPK) activity, an inhibitor of dual peroxisome proliferators activated receptor (PPAR) activity, an inhibitor of mevalonic-acid pyrophosphate decarboxylase, an inhibitor of the conversion of isopententyl pyrophosphate (IPP) to farnesyl pyrophosphate (FPP), an inhibitor of the isoprenylation of proteins, an inhibitor of the induction of NF-kβ

, an inhibitor of the farnesylation of Ras, an inhibitor of cAMP phosphodiesterase, an antioxidant that blocks LPS- and cytokine-induced production of NO, and an enhancer of intracellular levels of cAMP, and any combinations thereof.

15. The method of claim 14, wherein the prevention of type 1 diabetes mellitus in the patient in primary.

16. The method of claim 14, wherein the prevention of type 1 diabetes mellitus in the patient in secondary.

17. A method of treating type 1 diabetes mellitus in a juvenile patient in need of treatment comprising administering one or more therapeutic agents to the patient in an amount sufficient to increase the C-peptide level of the patient after at least six months as compared to the C-peptide level of the patient prior to treatment, wherein the therapeutic agents are selected from the group consisting of an inhibitor of mevalonate synthesis, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, an inducer of AMP protein kinase (AMPK) activity, an inhibitor of dual peroxisome proliferators activated receptor (PPAR) activity, an inhibitor of mevalonic-acid pyrophosphate decarboxylase, an inhibitor of the conversion of isopententyl pyrophosphate (IPP) to farnesyl pyrophosphate (FPP), an inhibitor of the isoprenylation of proteins, an inhibitor of the induction of NF-kβ

, an inhibitor of the farnesylation of Ras, an inhibitor of cAMP phosphodiesterase, an antioxidant that blocks LPS- and cytokine-induced production of NO, an enhancer of intracellular levels of cAMP, and any combinations thereof.

18. The method of claim 17, wherein the ratio of the C-peptide level of the patient after treatment compared to the C-peptide level of the patient prior to treatment is at least about 1.4 to 1.0.

19. The method of claim 17, wherein the C-peptide level of the patient after treatment compared to the C-peptide level of the patient prior to treatment increases at least about 3-fold.

20. The method of claim 17, wherein the amount of one or more therapeutic agents administered to the juvenile patient is sufficient to increase the C-peptide level of the patient after at least two years as compared to the C-peptide level of the patient prior to treatment.